Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019August 16, 2022 Alterity Therapeutics

Notice of General Meeting 2019

2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

Annual Report Filed on Form 20-F with SEC

September 7, 2017August 16, 2022

Prana AGM Investor Conference Call

November 11, 2018August 16, 2022

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

October 29, 2021May 23, 2023

Recent Posts

Chairman’s Address 2023 Annual General Meeting
AGM 2023 Presentation
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
Alterity Therapeutics Raises $4.8M AUD in Placement
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065